Cargando…

Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies

The advent of biologics and small molecules in inflammatory bowel disease (IBD) has marked a significant turning point in the prognosis of IBD, decreasing the rates of corticosteroid dependence, hospitalizations and improving overall quality of life. The introduction of biosimilars has also increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheah, Eric, Huang, James Guoxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037250/ https://www.ncbi.nlm.nih.gov/pubmed/36970587 http://dx.doi.org/10.3748/wjg.v29.i10.1539

Ejemplares similares

Systems biology in inflammatory bowel diseases: on the way to precision medicine
por: Dovrolis, Nikolas, et al.
Publicado: (2019)

Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
por: Xu, Yi-Han, et al.
Publicado: (2022)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease
por: Thomas, John P, et al.
Publicado: (2021)

Precision Medicine in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2021)

Precision Medicine in Inflammatory Bowel Disease
por: Annese, Vito, et al.
Publicado: (2023)

Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease
por: Ahmed, Waseem
Publicado: (2022)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
por: Balderramo, Domingo
Publicado: (2022)

Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2022)

Small Molecule Drugs in Inflammatory Bowel Diseases
por: Ben Ghezala, Inès, et al.
Publicado: (2021)

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
por: Jun, Yu Kyung, et al.
Publicado: (2023)

Precision medicine in inflammatory bowel disease: concept, progress and challenges
por: Borg-Bartolo, Simon P., et al.
Publicado: (2020)

Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease
por: Jagirdhar, Gowthami Sai Kogilathota, et al.
Publicado: (2023)

Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
por: Khoshnam-Rad, Niloofar, et al.
Publicado: (2023)

Precision medicine and drug optimization in adult inflammatory bowel disease patients
por: Vieujean, Sophie, et al.
Publicado: (2023)

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
por: Alayo, Quazim A, et al.
Publicado: (2022)

Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019)

Susceptibility gene profiling elucidates the pathogenesis of inflammatory bowel disease and provides precision medicine
por: Gao, Han, et al.
Publicado: (2023)

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
por: Na, Soo-Young, et al.
Publicado: (2022)

Advances in Precision Medicine: Tailoring Individualized Therapies
por: Matchett, Kyle B., et al.
Publicado: (2017)

Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Moran, Kellyn, et al.
Publicado: (2020)

Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
por: Bilal, Muhammad, et al.
Publicado: (2021)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies
por: Dulai, Parambir S., et al.
Publicado: (2019)

Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
por: Bressler, Brian
Publicado: (2023)

Comment on: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Woolcott, John, et al.
Publicado: (2020)

Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease
por: Wang, Liucan, et al.
Publicado: (2021)

Human Microbiome and Learning Healthcare Systems: Integrating Research and Precision Medicine for Inflammatory Bowel Disease
por: Chuong, Kim H., et al.
Publicado: (2018)

Small Bowel Endoscopy in Inflammatory Bowel Disease
por: Yamagami, Hirokazu, et al.
Publicado: (2013)

Optimizing the use of biological therapy in patients with inflammatory bowel disease
por: Moss, Alan C.
Publicado: (2015)

The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
por: Larsen, Lone, et al.
Publicado: (2016)

Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
por: Kim, Duk Hwan, et al.
Publicado: (2017)

Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease
por: Dong, Yumeng, et al.
Publicado: (2022)

Genetic polymorphisms of inflammatory molecules in Tunisian inflammatory bowel diseases
por: Gorgi, Y, et al.
Publicado: (2010)

Impact of biologics and small molecules for inflammatory bowel disease on COVID‐19‐related hospitalization and mortality: A systematic review and meta‐analysis
por: Alrashed, Fatema, et al.
Publicado: (2022)

Fecal Fungal Microbiota (Mycobiome) Study as a Potential Tool for Precision Medicine in Inflammatory Bowel Disease
por: Balderramo, Domingo C., et al.
Publicado: (2023)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
por: McCormack, Matthew D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uja06k1s5rc0uqvuud56vdtpb8